US 11,919,854 B2
P2RX7 modulators in therapy
Valérie Vouret, Nice (FR); Laetitia Douguet, Bailly (FR); Alina Ghinet, Lomme (FR); Germain Homerin, Lille (FR); Benoît Guy Marie Rigo, Lille (FR); Davy Jérémy Baudelet, Paris (FR); Xavier Dezitter, Marchiennes (FR); Régis Millet, Harnes (FR); and Christophe Furman, Marcq en Baroeul (FR)
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); CHRU DE LILLE, Lille (FR); UNIVERSITE COTE D'AZUR, Nice (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); UNIVERSITE DE LILLE, Lille (FR); and JUNIA, Lille (FR)
Appl. No. 17/042,806
Filed by Centre national de la recherche scientifique, Paris (FR); CHRU de Lille, Lille (FR); Universite Côte D'Azur, Nice (FR); Institut National de la Sante et de la Recherche Medicale (INSERM), Paris (FR); Université de Lille, Lille (FR); and YNCREA Hauts de France, Lille (FR)
PCT Filed Mar. 29, 2019, PCT No. PCT/EP2019/058013
§ 371(c)(1), (2) Date Sep. 28, 2020,
PCT Pub. No. WO2019/185868, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 18305361 (EP), filed on Mar. 29, 2018.
Prior Publication US 2021/0017131 A1, Jan. 21, 2021
Int. Cl. C07D 207/16 (2006.01); A61K 31/4015 (2006.01); A61K 31/4025 (2006.01); A61K 31/4439 (2006.01); A61K 39/395 (2006.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); C07D 401/12 (2006.01); C07D 409/12 (2006.01)
CPC C07D 207/16 (2013.01) [A61K 31/4015 (2013.01); A61K 31/4025 (2013.01); A61K 31/4439 (2013.01); A61K 39/395 (2013.01); A61P 1/00 (2018.01); A61P 35/00 (2018.01); C07D 401/12 (2013.01); C07D 409/12 (2013.01)] 15 Claims
 
1. A compound chosen from compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts:

OG Complex Work Unit Chemistry
in which:
R1 represents a C1 -C14 alkyl, a cycloalkyl group, a phenyl or biphenyl group, a benzyl group or a heteroaryl group selected from the group consisting of pyridine and thiophene, wherein said phenyl, biphenyl, benzyl or heteroaryl group is optionally substituted with at least one group selected from the group consisting of:
halogen atoms;
C1-C6 alkoxy radicals;
C1-C6 alkyl radicals; and
C1-C6 halogenoalkyl radicals, and
R2 represents an aryl group that is a phenyl, an aralkyl group that is a benzyl or phenethyl, or a cycloalkyl group, wherein said aryl group or said aralkyl group is optionally substituted with at least one group chosen from halogen atoms,
wherein R1 and R2 do not each simultaneously represent a phenyl group.